Literature DB >> 28792269

Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia.

Marla M Jalbut1,2, Andrew M Brunner1, Philip C Amrein1, Karen K Ballen1, Gabriela S Hobbs1, Ashley M Perry1, Christelle P Joseph1, Amir T Fathi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28792269      PMCID： PMC6197051          DOI： 10.1080/10428194.2017.1361028

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  15 in total

Review 1.  Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.

Authors:  Eyal Robenshtok; Anat Gafter-Gvili; Elad Goldberg; Miriam Weinberger; Moshe Yeshurun; Leonard Leibovici; Mical Paul
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

2.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

3.  Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.

Authors:  Haifa K Al-Ali; Nadja Jaekel; Christian Junghanss; Georg Maschmeyer; Rainer Krahl; Michael Cross; Gisa Hoppe; Dietger Niederwieser
Journal:  Leuk Lymphoma       Date:  2011-08-24

4.  Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

Authors:  Amanda F Cashen; Gary J Schiller; Margaret R O'Donnell; John F DiPersio
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

5.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

6.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Authors:  Hervé Dombret; John F Seymour; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal del Castillo; Haifa Kathrin Al-Ali; Giovanni Martinelli; Jose Falantes; Richard Noppeney; Richard M Stone; Mark D Minden; Heidi McIntyre; Steve Songer; Lela M Lucy; C L Beach; Hartmut Döhner
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

7.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

8.  Infections in acute myeloid leukemia: an analysis of 382 febrile episodes.

Authors:  Ajay Gupta; Mansher Singh; Harkirat Singh; Lalit Kumar; Atul Sharma; Sameer Bakhshi; Vinod Raina; Sanjay Thulkar
Journal:  Med Oncol       Date:  2009-10-15       Impact factor: 3.064

9.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

10.  Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia.

Authors:  R S Schwartz; F R Mackintosh; S L Schrier; P L Greenberg
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860
View more
  1 in total

1.  Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia.

Authors:  Romy Tober; Ulf Schnetzke; Maximilian Fleischmann; Olaposi Yomade; Karin Schrenk; Jakob Hammersen; Anita Glaser; Christian Thiede; Andreas Hochhaus; Sebastian Scholl
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-18       Impact factor: 4.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.